Giacomo Nuvola, Medical Manager – Oncology at Pivotal, shared a post on LinkedIn:
“ASCO 2026 is becoming a defining moment for GU oncology – not only from a clinical perspective, but also for pharma, biotech, diagnostics, and CRO strategy.
These are the 5 GU topics I’ll be watching most closely at ASCO26:
PROTEUS trial
Perioperative intensification in high-risk localized prostate cancer may move systemic treatment earlier than ever before.
TALAPRO-3 trial
PARP inhibitors continue their expansion into hormone-sensitive disease, reinforcing the central role of biomarker-driven development.
EV-302 trial long-term follow-up
Enfortumab vedotin + pembrolizumab is no longer just a promising combination – durability data may redefine expectations in metastatic urothelial carcinoma.
RAMPART trial
The adjuvant RCC debate continues. The key question is no longer only efficacy, but patient selection and value optimization.
ctDNA / MRD-driven strategies
Perhaps the most important long-term theme across GU oncology:
using molecular residual disease to guide escalation, de-escalation, bladder preservation, and smarter trial design.
From an industry and CRO perspective, ASCO 2026 highlights several major trends:
- Earlier-stage drug development is becoming increasingly aggressive
- Biomarker integration is now mandatory, not optional
- Companion diagnostics and centralized testing will continue to expand
- Adaptive and MRD-driven trial designs are accelerating
- Cross-functional execution between sponsors, CROs, diagnostics, and sites is becoming more critical than ever
The future of GU oncology will not only depend on better drugs, but on better patient selection, smarter development strategies, and faster operational execution.
Curious to see which abstracts ultimately become truly practice-changing.”
Other articles on OncoDaily.